Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam
Keyword(s):
Abstract This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)–3–producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC–Klebsiella pneumoniae central nervous system infections.
1990 ◽
Vol 10
(2)
◽
pp. 88-95
◽
2018 ◽
Vol 32
(5)
◽
pp. 589-594
◽
2016 ◽
Vol 1009-1010
◽
pp. 138-143
◽
2015 ◽
Vol 78
(2)
◽
pp. 78
◽
2007 ◽
Vol 23
(6)
◽
pp. 344-348
◽